These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1747507)

  • 1. Effect of physical exercise on one-sample antipyrine clearance.
    Fabbri A; Bianchi G; Zoli M; Marchi E; Marchesini G
    Ital J Gastroenterol; 1991 Feb; 23(2):74-6. PubMed ID: 1747507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.
    Rautio A; Kauppila AJ; Tuimala RJ; Sotaniemi EA
    Biomedicine; 1979 Sep; 31(5):135-8. PubMed ID: 508896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
    Mahmoud M; Abdel-Kader R; Hassanein M; Saleh S; Botros S
    Eur J Pharmacol; 2007 Aug; 569(3):222-7. PubMed ID: 17628532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic drug clearance in patients with mild cystic fibrosis.
    Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
    Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the capacity of the liver for phenazone biotransformation in patients with uremia on peritoneal dialysis].
    Grzegorzewska A; Lowicki Z; Chmara E; Mrozikiewicz A; Baczyk K
    Pol Tyg Lek; 1990 Apr 16-30; 45(16-18):339-41. PubMed ID: 2235722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects.
    Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S79-88. PubMed ID: 3842695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
    Coverdale SA; Samarasinghe DA; Lin R; Kench J; Byth K; Khan MH; Crewe E; Liddle C; George J; Farrell GC
    Am J Gastroenterol; 2003 Jun; 98(6):1384-90. PubMed ID: 12818285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of metabolic efficiency of the liver in patients with psoriasis by the antipyrine test].
    Bienias L; Czarnecki M; Kaszuba A; Ruszczak Z; Kozłowska M; Bednarowicz G; Drobnik G
    Przegl Dermatol; 1990; 77(5):301-6. PubMed ID: 2270292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
    von Mandach U; Jost G; Preisig R
    Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of six beta-adrenolytics and labetalol on hepatic biotransformation studied by antipyrine test, in man.
    Adamska-Dyniewska H; Dziekański S; Pruszczyński J
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):303-7. PubMed ID: 2874117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
    Oltmanns D; Dennin DE; Pentz R; Siegers CP
    Z Gastroenterol; 1984 Oct; 22(10):598-601. PubMed ID: 6506825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exercise training does not alter cytochrome P-450 content and microsomal metabolism.
    Michaud TJ; Bachmann KA; Andres FF; Flynn MG; Sherman GP; Rodriguez-Zayas J
    Med Sci Sports Exerc; 1994 Aug; 26(8):978-82. PubMed ID: 7968432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipyrine metabolism and bronchogenic carcinoma.
    Ambre J; Graeff D; Bures F; Haupt D; Deason K
    J Med; 1977; 8(1):57-70. PubMed ID: 267157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the antipyrine test in laboratory animals. Studies in the dog and monkey.
    Vickers FF; Bowman TA; Dvorchik BH; Passananti GT; Hughes DM; Vesell ES
    Drug Metab Dispos; 1989; 17(2):160-5. PubMed ID: 2565205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.
    Reimann G; Barthel B; Rockstroh JK; Spatz D; Brockmeyer NH
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):562-6. PubMed ID: 10584978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
    Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
    Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The assessment of liver microsomal oxidative capacity via caffeine and antipyrine elimination in patients with chronic active hepatitis: preliminary results].
    Soto Alvarez J; Alsar Ortiz MJ
    An Med Interna; 1992 Nov; 9(11):547-50. PubMed ID: 1467403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver failure and drug metabolism.
    Andreasen PB; Ranek L
    Scand J Gastroenterol; 1975; 10(3):293-7. PubMed ID: 1138332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of single sample clearance estimates to probe hepatic drug metabolism in rats. I.
    Bachmann KA; Yang C; Jahn D; Schwartz J
    Xenobiotica; 1988 Feb; 18(2):151-9. PubMed ID: 3131969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.